Cardiovascular event rate modifies response to pharmacologic LDL-C lowering in primary prevention: implications of a systematic review and meta-analysis for clinical practice
Abstract
Background LDL-C lowering is often delayed in lower-risk primary-prevention settings as absolute benefits appear modest. Trial evidence for greater relative benefits from pharmacologic LDL-C lowering in lower-risk individuals, supporting genetic studies, could strengthen the rationale for initiating LDL-C-lowering therapies at lower-risk levels. Objectives To quantify i) how RRR for 3P-MACE per 1mmol/L LDL-C-lowering varies by baseline risk, ii) the absolute LDL-C reduction required to achieve 25 % RRR at varying risk thresholds. Methods Systematic review and meta-analysis using EMBASE, MEDLINE, and CENTRAL searches for randomized, placebo-controlled lipid-lowering trials in populations with no or low (
Fields of Study & Subjects
Lipoproteins and Cardiovascular Health
Diabetes
Cardiovascular Risks
and Lipoproteins
Atherosclerosis and Cardiovascular Diseases
Publication details
- Journal / source
- American Journal of Preventive Cardiology
- Publisher
- Elsevier BV
- Volume
- 28
- Pages
- 101655–101655
- Publication date
- 25 May 2026
- Language
- EN